Top

Published in:

01-03-2021 | Breast Cancer | Original Article

Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8⁺ T cell augmentation

Authors: Chuan-Kun Shan, Yi-Bo Du, Xiao-Tian Zhai, Yue-Xuan Wang, Yi Li, Jian-Hua Gong, Zhi-Juan Ge, Xiu-Jun Liu, Yong-Su Zhen

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2021

Abstract

Purpose

To investigate the antitumor efficacy of pingyangmycin (PYM) in combination with anti-PD-1 antibody and determine the capability of PYM to induce immunogenic cell death (ICD) in cancer cells.

Methods

The murine 4T1 breast cancer and B16 melanoma models were used for evaluation of therapeutic efficacy of the combination of PYM with anti-PD-1 antibody. The ELISA kits were used to quantify the ICD related ATP and HMGB1 levels. The Transwell assay was conducted to determine the chemotaxis ability of THP-1 cell in vitro. The flow cytometry was used to measure reactive oxygen species level and analyze the ratio of immune cell subsets.

Results

PYM induced ICD in murine 4T1 breast cancer and B16 melanoma cells and increased the release of nucleic acid fragments that may further promote the monocytic chemotaxis. In the 4T1 murine breast cancer model, PYM alone, anti-PD-1 antibody alone, and their combination suppressed tumor growth by 66.3%, 16.1% and 77.6%, respectively. PYM markedly enhanced the therapeutic efficacy of anti-PD-1 antibody against 4T1 breast cancer. The calculated CDI (coefficient of drug interaction) indicated synergistic effect. Evaluated by graphic analysis, the nucleated cells intensity in the femur bone marrow remained unchanged. Histopathological observations revealed no noticeable toxico-pathological changes in the lung and various organs, indicating that the PYM and anti-PD-1 antibody combination exerted enhanced efficacy at well-tolerated dosage level. By the combination treatment, a panel of immunological changes emerged. The ratio of CD3⁺ cells, NK cells and NKT cells increased and Tregs decreased in peripheral blood. The DCs increased in the spleen. Prominent changes occurred in tumor infiltrating lymphocytes. The ratio of CD8⁺ cells increased, while that of CD4⁺ cells decreased; however, the ratio of CD3⁺ cells remained unchanged, implying that certain immunological responses emerged in the tumor microenvironment. PYM alone could also increase CD8⁺ cells and reduce CD4⁺ cells in tumor infiltrating lymphocytes.

Conclusions

The studies indicate that PYM, as an ICD inducer with mild myelosuppression effect, may enhance the therapeutic efficacy of anti-PD-1 antibody in association with tumor infiltrating CD8⁺ T cell augmentation.

Available only for authorised users

Luo Q, Zhang L, Luo C, Jiang M (2019) Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett 454:191–203. https://doi.org/10.1016/j.canlet.2019.04.017CrossRefPubMed

Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. https://doi.org/10.1056/NEJMoa1503093CrossRefPubMed

Ansell SM (2019) Pembrolizumab: living up to expectations. Blood 134:1114–1115. https://doi.org/10.1182/blood.2019002417CrossRefPubMed

Mason R, Dearden HC, Nguyen B et al (2020) Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell Melanoma Res 33:358–365. https://doi.org/10.1111/pcmr.12831CrossRefPubMed

Smyth EC, Lordick F (2019) Nivolumab for previously treated squamous oesophageal carcinoma. Lancet Oncol 20:1468–1469. https://doi.org/10.1016/S1470-2045(19)30621-7CrossRefPubMed

Genova C, Boccardo S, Mora M et al (2019) Correlation between B7–H4 and survival of non-small-cell lung cancer patients treated with nivolumab. J Clin Med 8:1566. https://doi.org/10.3390/jcm8101566CrossRefPubMedCentral

Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72. https://doi.org/10.1146/annurev-immunol-032712-100008CrossRefPubMed

Inoue H, Tani K (2014) Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21:39–49. https://doi.org/10.1038/cdd.2013.84CrossRefPubMed

Golchin S, Alimohammadi R, Rostami Nejad M, Jalali SA (2019) Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. J Cell Physiol. https://doi.org/10.1002/jcp.28585CrossRefPubMed

10.

Wu J, Waxman DJ (2018) Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 419:210–221. https://doi.org/10.1016/j.canlet.2018.01.050CrossRefPubMedPubMedCentral

11.

Gong J, Liu X, Li Y, Zhen Y (2012) Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemother Pharmacol 69:1323–1332. https://doi.org/10.1007/s00280-012-1827-9CrossRefPubMed

12.

Tai K-W, Chang Y-C, Shin-Shen Chou L, Chou M-Y (1998) Cytotoxic effect of pingyangmycin on cultured KB cells. Oral Oncol 34:219–223. https://doi.org/10.1016/S1368-8375(97)00089-4CrossRefPubMed

13.

Sergeyev DS, Godovikova TS, Zarytova VF (1991) Direct cleavage of a DNA fragment by a bleomycin-oligonucleotide derivative. FEBS Lett 280:271–273. https://doi.org/10.1016/0014-5793(91)80309-qCrossRefPubMed

14.

Zhang H, Ma Y, Zhang S, et al (2015) Involvement of Ras GTPase-activating protein SH3 domain-binding protein 1 in the epithelial-to-mesenchymal transition-induced metastasis of breast cancer cells via the Smad signaling pathway. Oncotarget https://doi.org/10.18632/oncotarget.3636

15.

Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58:1486–1493PubMed

16.

Elliott MR, Chekeni FB, Trampont PC et al (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282–286. https://doi.org/10.1038/nature08296CrossRefPubMedPubMedCentral

17.

Cao SS, Zhen YS (1989) Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 24:181–186. https://doi.org/10.1007/bf00300240CrossRefPubMed

18.

Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1–10. https://doi.org/10.1016/j.immuni.2013.07.012CrossRefPubMed

19.

Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480–489. https://doi.org/10.1038/nature10673CrossRefPubMedPubMedCentral

20.

Sathyanarayanan V, Neelapu SS (2015) Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Molec Oncol 9:2043–2053. https://doi.org/10.1016/j.molonc.2015.10.009CrossRef

21.

Gotwals P, Cameron S, Cipolletta D et al (2017) Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer 17:286–301. https://doi.org/10.1038/nrc.2017.17CrossRefPubMed

22.

Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol 39:98–106. https://doi.org/10.1097/COC.0000000000000239CrossRefPubMedPubMedCentral

23.

Vera Aguilera J, Paludo J, McWilliams RR, et al (2020) Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res Publish Ahead of Print https://doi.org/10.1097/CMR.0000000000000669

24.

Zhou J, Wang G, Chen Y et al (2019) Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med 23:4854–4865. https://doi.org/10.1111/jcmm.14356CrossRefPubMedPubMedCentral

25.

Lamberti MJ, Nigro A, Mentucci FM et al (2020) Dendritic cells and immunogenic cancer cell death: a combination for improving antitumor immunity. Pharmaceutics 12:256. https://doi.org/10.3390/pharmaceutics12030256CrossRefPubMedCentral

26.

Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160. https://doi.org/10.1038/nrclinonc.2010.223CrossRefPubMed

27.

Michaud M, Martins I, Sukkurwala AQ et al (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334:1573–1577. https://doi.org/10.1126/science.1208347CrossRefPubMed

28.

Park J, Kim CG, Shim J-K et al (2018) Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. Oncoimmunology. https://doi.org/10.1080/2162402X.2018.1525243CrossRefPubMedPubMedCentral

29.

Li Y, Zhang H, Li Q et al (2020) CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Lett 495:12–21. https://doi.org/10.1016/j.canlet.2020.09.011CrossRefPubMed

30.

Lotsberg ML, Wnuk-Lipinska K, Terry S et al (2020) AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug-resistant cancer cells. J Thoracic Oncol 15:973–999. https://doi.org/10.1016/j.jtho.2020.01.015CrossRef

31.

Lau TS, Chan LKY, Man GCW et al (2020) Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis. Cancer Immunol Res 8:1099–1111. https://doi.org/10.1158/2326-6066.CIR-19-0616CrossRefPubMed

32.

Du B, Waxman DJ (2020) Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Lett 470:170–180. https://doi.org/10.1016/j.canlet.2019.11.025CrossRefPubMed

33.

Duraiswamy J, Freeman GJ, Coukos G (2014) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors–response. Cancer Res 74:633–634. https://doi.org/10.1158/0008-5472.CAN-13-2752CrossRefPubMed

34.

Woo S-R, Turnis ME, Goldberg MV et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917–927. https://doi.org/10.1158/0008-5472.CAN-11-1620CrossRef

35.

Krantz D, Hartana CA, Winerdal ME et al (2018) Neoadjuvant chemotherapy reinforces antitumour T cell response in urothelial urinary bladder cancer. Eur Urol 74:688–692. https://doi.org/10.1016/j.eururo.2018.06.048CrossRefPubMed

36.

Xiang Y, Chen L, Li L, Huang Y (2020) Restoration and enhancement of immunogenic cell death of cisplatin by coadministration with digoxin and conjugation to HPMA copolymer. ACS Appl Mater Interfaces 12:1606–1616. https://doi.org/10.1021/acsami.9b19323CrossRefPubMed

37.

Park S-J, Ye W, Xiao R et al (2019) Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncol 95:127–135. https://doi.org/10.1016/j.oraloncology.2019.06.016CrossRefPubMedPubMedCentral

38.

Vignali DAA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523–532. https://doi.org/10.1038/nri2343CrossRefPubMedPubMedCentral

39.

Lee JC, Mehdizadeh S, Smith J et al (2020) Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol 5:eaba0759. https://doi.org/10.1126/sciimmunol.aba0759CrossRefPubMed

40.

Chen G, Emens LA (2013) Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 62:203–216. https://doi.org/10.1007/s00262-012-1388-0CrossRefPubMedPubMedCentral

41.

Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 58:1627–1634. https://doi.org/10.1007/s00262-009-0671-1CrossRefPubMed

42.

Sistigu A, Viaud S, Chaput N et al (2011) Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 33:369–383. https://doi.org/10.1007/s00281-011-0245-0CrossRefPubMed

Title: Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation
Authors: Chuan-Kun Shan
Yi-Bo Du
Xiao-Tian Zhai
Yue-Xuan Wang
Yi Li
Jian-Hua Gong
Zhi-Juan Ge
Xiu-Jun Liu
Yong-Su Zhen
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2021
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-020-04209-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2021

The use of zebrafish model in prostate cancer therapeutic development and discovery

Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed

Irinotecan-induced intestinal mucositis in mice: a histopathological study

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors

FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway

Involvement of cytochrome P450 enzymes in inflammation and cancer: a review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer